{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:11:45Z","timestamp":1793607105120,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T00:00:00Z","timestamp":1637193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R249-2017-851"],"award-info":[{"award-number":["R249-2017-851"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["DFF \u2013 7025-00106"],"award-info":[{"award-number":["DFF \u2013 7025-00106"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["DFF \u2013 7016-00310"],"award-info":[{"award-number":["DFF \u2013 7016-00310"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI135721"],"award-info":[{"award-number":["R01AI135721"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N9301900067"],"award-info":[{"award-number":["75N9301900067"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Given the encouraging clinical results of both candidate subunit vaccines and revaccination with Bacillus Calmette-Gu\u00e9rin (BCG) against tuberculosis (TB), there is support for combining BCG and subunit vaccination for increased efficacy. BCG and\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    (Mtb) share ~98% of their genome and current subunit vaccines are almost exclusively designed as BCG boosters. The goal of this study is to design a TB subunit vaccine composed of antigens not shared with BCG and explore the advantages of this design in a BCG\u2009+\u2009subunit co-administration vaccine strategy. Eight protective antigens are selected to create an Mtb-specific subunit vaccine, named H107. Whereas traditional vaccines containing BCG-shared antigens exhibit in vivo cross-reactivity to BCG, H107 shows no cross-reactivity and does not inhibit BCG colonization. Instead, co-administering H107 with BCG leads to increased adaptive responses against both H107 and BCG. Importantly, rather than expanding BCG-primed T cells, H107 broadens the overall vaccine repertoire with new T cell clones and introduces \u2018adjuvant-imprinted\u2019 qualities including Th17 responses and less-differentiated Th1 cells. Collectively, these features of H107 are associated with a substantial increase in long-term protection.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-26934-0","type":"journal-article","created":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T06:03:09Z","timestamp":1637215389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Gu\u00e9rin"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0771-9056","authenticated-orcid":false,"given":"Joshua S.","family":"Woodworth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2994-3120","authenticated-orcid":false,"given":"Helena Strand","family":"Clemmensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Battey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5395-505X","authenticated-orcid":false,"given":"Karin","family":"Dijkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7162-8124","authenticated-orcid":false,"given":"Thomas","family":"Lindenstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Salvador","family":"Laureano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Taplitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Aagaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Rosenkrands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7302-8002","authenticated-orcid":false,"given":"Cecilia S.","family":"Lindestam Arlehamn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-3032","authenticated-orcid":false,"given":"Rasmus","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,18]]},"reference":[{"key":"26934_CR1","unstructured":"Global tuberculosis report 2020. World Health Organization (2020)."},{"key":"26934_CR2","doi-asserted-by":"publisher","first-page":"e1132","DOI":"10.1016\/S2214-109X(20)30288-6","volume":"8","author":"AB Hogan","year":"2020","unstructured":"Hogan, A. B. et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study. Lancet Glob. Health 8, e1132\u2013e1141 (2020).","journal-title":"Lancet Glob. Health"},{"key":"26934_CR3","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/resp.13304","volume":"23","author":"C Lange","year":"2018","unstructured":"Lange, C. et al. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology 23, 656\u2013673 (2018).","journal-title":"Respirology"},{"key":"26934_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/S0140-6736(95)92348-9","volume":"346","author":"PE Fine","year":"1995","unstructured":"Fine, P. E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346, 1339\u20131345 (1995).","journal-title":"Lancet"},{"key":"26934_CR5","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1128\/IAI.70.2.672-678.2002","volume":"70","author":"L Brandt","year":"2002","unstructured":"Brandt, L. et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect. Immun. 70, 672\u2013678 (2002).","journal-title":"Infect. Immun."},{"key":"26934_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.tube.2013.12.006","volume":"94","author":"HC Poyntz","year":"2014","unstructured":"Poyntz, H. C. et al. Non-tuberculous mycobacteria have diverse effects on BCG efficacy against Mycobacterium tuberculosis. Tuberculosis (Edinb.) 94, 226\u2013237 (2014).","journal-title":"Tuberculosis (Edinb.)"},{"key":"26934_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/S0140-6736(05)67145-0","volume":"366","author":"LC Rodrigues","year":"2005","unstructured":"Rodrigues, L. C. et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 366, 1290\u20131295 (2005).","journal-title":"Lancet"},{"key":"26934_CR8","doi-asserted-by":"publisher","first-page":"c671","DOI":"10.1136\/bmj.c671","volume":"340","author":"AE Roth","year":"2010","unstructured":"Roth, A. E. et al. Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau. BMJ 340, c671 (2010).","journal-title":"BMJ"},{"key":"26934_CR9","first-page":"717","volume":"5","author":"CC Leung","year":"2001","unstructured":"Leung, C. C. et al. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. Int J. Tuberc. Lung Dis. 5, 717\u2013723 (2001).","journal-title":"Int J. Tuberc. Lung Dis."},{"key":"26934_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0140-6736(96)02166-6","volume":"348","author":"KPT Group","year":"1996","unstructured":"Group, K. P. T. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 348, 17\u201324 (1996).","journal-title":"Lancet"},{"key":"26934_CR11","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1016\/j.vaccine.2011.05.023","volume":"29","author":"ML Barreto","year":"2011","unstructured":"Barreto, M. L. et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial. Vaccine 29, 4875\u20134877 (2011).","journal-title":"Vaccine"},{"key":"26934_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes, E. et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N. Engl. J. Med. 379, 138\u2013149 (2018).","journal-title":"N. Engl. J. Med."},{"key":"26934_CR13","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","volume":"381","author":"DR Tait","year":"2019","unstructured":"Tait, D. R. et al. Final Analysis of a Trial of M72\/AS01E Vaccine to Prevent Tuberculosis. N. Engl. J. Med. 381, 2429\u20132439 (2019).","journal-title":"N. Engl. J. Med."},{"key":"26934_CR14","doi-asserted-by":"publisher","first-page":"15520","DOI":"10.1073\/pnas.1404386111","volume":"111","author":"GM Knight","year":"2014","unstructured":"Knight, G. M. et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc. Natl Acad. Sci. USA 111, 15520\u201315525 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26934_CR15","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S1473-3099(19)30625-5","volume":"20","author":"LK Schrager","year":"2020","unstructured":"Schrager, L. K., Vekemens, J., Drager, N., Lewinsohn, D. M. & Olesen, O. F. The status of tuberculosis vaccine development. Lancet Infect. Dis. 20, e28\u2013e37 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"26934_CR16","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMe1812483","volume":"379","author":"BR Bloom","year":"2018","unstructured":"Bloom, B. R. New Promise for Vaccines against Tuberculosis. N. Engl. J. Med. 379, 1672\u20131674 (2018).","journal-title":"N. Engl. J. Med."},{"key":"26934_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.12688\/f1000research.13588.1","volume":"7","author":"G Voss","year":"2018","unstructured":"Voss, G. et al. Progress and challenges in TB vaccine development. F1000Res 7, 199 (2018).","journal-title":"F1000Res"},{"key":"26934_CR18","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41577-019-0174-z","volume":"19","author":"P Andersen","year":"2019","unstructured":"Andersen, P. & Scriba, T. J. Moving tuberculosis vaccines from theory to practice. Nat. Rev. Immunol. 19, 550\u2013562 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"26934_CR19","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(18)30421-3","volume":"18","author":"LK Schrager","year":"2018","unstructured":"Schrager, L. K. et al. WHO preferred product characteristics for new vaccines against tuberculosis. Lancet Infect. Dis. 18, 828\u2013829 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"26934_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ebiom.2017.12.004","volume":"27","author":"T Lindenstrom","year":"2018","unstructured":"Lindenstrom, T. et al. Cells Primed by Live Mycobacteria Versus a Tuberculosis Subunit Vaccine Exhibit Distinct Functional Properties. EBioMedicine 27, 27\u201339 (2018).","journal-title":"EBioMedicine"},{"key":"26934_CR21","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/infdis\/jiv332","volume":"212","author":"J Leentjens","year":"2015","unstructured":"Leentjens, J. et al. BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. J. Infect. Dis. 212, 1930\u20131938 (2015).","journal-title":"J. Infect. Dis."},{"key":"26934_CR22","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.4049\/jimmunol.178.6.3721","volume":"178","author":"J Dietrich","year":"2007","unstructured":"Dietrich, J., Billeskov, R., Doherty, T. M. & Andersen, P. Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J. Immunol. 178, 3721\u20133730 (2007).","journal-title":"J. Immunol."},{"key":"26934_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.4049\/jimmunol.168.2.919","volume":"168","author":"MO Ota","year":"2002","unstructured":"Ota, M. O. et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168, 919\u2013925 (2002).","journal-title":"J. Immunol."},{"key":"26934_CR24","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1126\/science.284.5419.1520","volume":"284","author":"MA Behr","year":"1999","unstructured":"Behr, M. A. et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284, 1520\u20131523 (1999).","journal-title":"Science"},{"key":"26934_CR25","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/31159","volume":"393","author":"ST Cole","year":"1998","unstructured":"Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537\u2013544 (1998).","journal-title":"Nature"},{"key":"26934_CR26","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1111\/j.1365-2958.2005.04618.x","volume":"56","author":"D Charlet","year":"2005","unstructured":"Charlet, D. et al. Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK. Mol. Microbiol 56, 1302\u20131313 (2005).","journal-title":"Mol. Microbiol"},{"key":"26934_CR27","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1016\/S0264-410X(03)00484-5","volume":"21","author":"S Mostowy","year":"2003","unstructured":"Mostowy, S., Tsolaki, A. G., Small, P. M. & Behr, M. A. The in vitro evolution of BCG vaccines. Vaccine 21, 4270\u20134274 (2003).","journal-title":"Vaccine"},{"key":"26934_CR28","doi-asserted-by":"publisher","first-page":"e3116","DOI":"10.1371\/journal.pone.0003116","volume":"3","author":"EM Agger","year":"2008","unstructured":"Agger, E. M. et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PloS one 3, e3116 (2008).","journal-title":"PloS one"},{"key":"26934_CR29","doi-asserted-by":"publisher","first-page":"e1005760","DOI":"10.1371\/journal.ppat.1005760","volume":"12","author":"CS Lindestam Arlehamn","year":"2016","unstructured":"Lindestam Arlehamn, C. S. et al. A Quantitative Analysis of Complexity of Human Pathogen-Specific CD4 T Cell Responses in Healthy M. tuberculosis Infected South Africans. PLoS Pathog. 12, e1005760 (2016).","journal-title":"PLoS Pathog."},{"key":"26934_CR30","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1128\/IAI.00267-10","volume":"78","author":"M Sali","year":"2010","unstructured":"Sali, M. et al. Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect. Immun. 78, 5202\u20135213 (2010).","journal-title":"Infect. Immun."},{"key":"26934_CR31","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1128\/IAI.67.4.1702-1707.1999","volume":"67","author":"AT Kamath","year":"1999","unstructured":"Kamath, A. T., Feng, C. G., Macdonald, M., Briscoe, H. & Britton, W. J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect. Immun. 67, 1702\u20131707 (1999).","journal-title":"Infect. Immun."},{"key":"26934_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/srep45969","volume":"7","author":"M Ruhwald","year":"2017","unstructured":"Ruhwald, M. et al. Introducing the ESAT-6 free IGRA, a companion diagnostic for TB vaccines based on ESAT-6. Sci. Rep. 7, 45969 (2017).","journal-title":"Sci. Rep."},{"key":"26934_CR33","doi-asserted-by":"publisher","first-page":"585359","DOI":"10.3389\/fimmu.2020.585359","volume":"11","author":"HS Clemmensen","year":"2020","unstructured":"Clemmensen, H. S. et al. Rescuing ESAT-6 Specific CD4 T Cells From Terminal Differentiation Is Critical for Long-Term Control of Murine Mtb Infection. Front Immunol. 11, 585359 (2020).","journal-title":"Front Immunol."},{"key":"26934_CR34","doi-asserted-by":"publisher","first-page":"e80579","DOI":"10.1371\/journal.pone.0080579","volume":"8","author":"T Hoang","year":"2013","unstructured":"Hoang, T. et al. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS One 8, e80579 (2013).","journal-title":"PLoS One"},{"key":"26934_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nm859","volume":"9","author":"AS Pym","year":"2003","unstructured":"Pym, A. S. et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9, 533\u2013539 (2003).","journal-title":"Nat. Med"},{"key":"26934_CR36","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/infdis\/jiv137","volume":"212","author":"AW Olsen","year":"2015","unstructured":"Olsen, A. W., Follmann, F., Erneholm, K., Rosenkrands, I. & Andersen, P. Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. J. Infect. Dis. 212, 978\u2013989 (2015).","journal-title":"J. Infect. Dis."},{"key":"26934_CR37","doi-asserted-by":"publisher","first-page":"e39909","DOI":"10.1371\/journal.pone.0039909","volume":"7","author":"R Billeskov","year":"2012","unstructured":"Billeskov, R., Elvang, T. T., Andersen, P. L. & Dietrich, J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 7, e39909 (2012).","journal-title":"PLoS One"},{"key":"26934_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/srep19570","volume":"6","author":"NP Knudsen","year":"2016","unstructured":"Knudsen, N. P. et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci. Rep. 6, 19570 (2016).","journal-title":"Sci. Rep."},{"key":"26934_CR39","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.4049\/jimmunol.2000563","volume":"205","author":"C Aagaard","year":"2020","unstructured":"Aagaard, C. et al. Immunization with Mycobacterium tuberculosis-Specific Antigens Bypasses T Cell Differentiation from Prior Bacillus Calmette-Guerin Vaccination and Improves Protection in Mice. J. Immunol. 205, 2146\u20132155 (2020).","journal-title":"J. Immunol."},{"key":"26934_CR40","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.4049\/jimmunol.2000563","volume":"205","author":"C Aagaard","year":"2020","unstructured":"Aagaard, C. et al. Immunization with Mycobacterium tuberculosis\u2013Specific Antigens Bypasses T Cell Differentiation from Prior Bacillus Calmette\u2013Gu\u00e9rin Vaccination and Improves Protection in Mice. J. Immunol. 205, 2146\u20132155 (2020).","journal-title":"J. Immunol."},{"key":"26934_CR41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.chom.2017.05.012","volume":"21","author":"AO Moguche","year":"2017","unstructured":"Moguche, A. O. et al. Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis. Cell Host Microbe 21, 695\u2013706 e695 (2017).","journal-title":"Cell Host Microbe"},{"key":"26934_CR42","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1128\/IAI.00550-12","volume":"80","author":"T Lindenstrom","year":"2012","unstructured":"Lindenstrom, T. et al. Vaccine-induced th17 cells are maintained long-term postvaccination as a distinct and phenotypically stable memory subset. Infect. Immun. 80, 3533\u20133544 (2012).","journal-title":"Infect. Immun."},{"key":"26934_CR43","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/s41385-019-0145-5","volume":"12","author":"JS Woodworth","year":"2019","unstructured":"Woodworth, J. S. et al. Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection. Mucosal Immunol. 12, 816\u2013826 (2019).","journal-title":"Mucosal Immunol."},{"key":"26934_CR44","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.3389\/fmicb.2019.03154","volume":"10","author":"M Hatherill","year":"2019","unstructured":"Hatherill, M., White, R. G. & Hawn, T. R. Clinical Development of New TB Vaccines: Recent Advances and Next Steps. Front Microbiol. 10, 3154 (2019).","journal-title":"Front Microbiol"},{"key":"26934_CR45","doi-asserted-by":"publisher","first-page":"e1007643","DOI":"10.1371\/journal.ppat.1007643","volume":"15","author":"MJ Rodo","year":"2019","unstructured":"Rodo, M. J. et al. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathog. 15, e1007643 (2019).","journal-title":"PLoS Pathog."},{"key":"26934_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","volume":"577","author":"PA Darrah","year":"2020","unstructured":"Darrah, P. A. et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 577, 95\u2013102 (2020).","journal-title":"Nature"},{"key":"26934_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41591-018-0319-9","volume":"25","author":"K Dijkman","year":"2019","unstructured":"Dijkman, K. et al. Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nat. Med 25, 255\u2013262 (2019).","journal-title":"Nat. Med"},{"key":"26934_CR48","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1073\/pnas.1314973111","volume":"111","author":"NP Knudsen","year":"2014","unstructured":"Knudsen, N. P. et al. Tuberculosis vaccine with high predicted population coverage and compatibility with modern diagnostics. Proc. Natl Acad. Sci. USA 111, 1096\u20131101 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26934_CR49","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.3389\/fimmu.2017.01147","volume":"8","author":"NE Nieuwenhuizen","year":"2017","unstructured":"Nieuwenhuizen, N. E. et al. The Recombinant Bacille Calmette-Guerin Vaccine VPM1002: Ready for Clinical Efficacy Testing. Front. Immunol. 8, 1147 (2017).","journal-title":"Front. Immunol."},{"key":"26934_CR50","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.tube.2009.03.002","volume":"89","author":"N Ritz","year":"2009","unstructured":"Ritz, N. & Curtis, N. Mapping the global use of different BCG vaccine strains. Tuberculosis (Edinb.) 89, 248\u2013251 (2009).","journal-title":"Tuberculosis (Edinb.)"},{"key":"26934_CR51","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.vaccine.2017.12.010","volume":"36","author":"T Cernuschi","year":"2018","unstructured":"Cernuschi, T., Malvolti, S., Nickels, E. & Friede, M. Bacillus Calmette-Guerin (BCG) vaccine: A global assessment of demand and supply balance. Vaccine 36, 498\u2013506 (2018).","journal-title":"Vaccine"},{"key":"26934_CR52","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1093\/hmg\/ddp372","volume":"18","author":"AC Antoniou","year":"2009","unstructured":"Antoniou, A. C. et al. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum. Mol. Genet. 18, 4442\u20134456 (2009).","journal-title":"Hum. Mol. Genet."},{"key":"26934_CR53","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/eji.200940017","volume":"40","author":"G Di Genova","year":"2010","unstructured":"Di Genova, G., Savelyeva, N., Suchacki, A., Thirdborough, S. M. & Stevenson, F. K. Bystander stimulation of activated CD4\u2009+\u2009T cells of unrelated specificity following a booster vaccination with tetanus toxoid. Eur. J. Immunol. 40, 976\u2013985 (2010).","journal-title":"Eur. J. Immunol."},{"key":"26934_CR54","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.4049\/jimmunol.1400019","volume":"192","author":"S Sakai","year":"2014","unstructured":"Sakai, S. et al. Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells. J. Immunol. 192, 2965\u20132969 (2014).","journal-title":"J. Immunol."},{"key":"26934_CR55","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1016\/j.celrep.2017.03.007","volume":"18","author":"MA Sallin","year":"2017","unstructured":"Sallin, M. A. et al. Th1 Differentiation Drives the Accumulation of Intravascular, Non-protective CD4 T Cells during Tuberculosis. Cell Rep. 18, 3091\u20133104 (2017).","journal-title":"Cell Rep."},{"key":"26934_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16085","volume":"8","author":"N Aguilo","year":"2017","unstructured":"Aguilo, N. et al. Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosis. Nat. Commun. 8, 16085 (2017).","journal-title":"Nat. Commun."},{"key":"26934_CR57","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1016\/j.vaccine.2015.03.083","volume":"33","author":"D Bottai","year":"2015","unstructured":"Bottai, D. et al. Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. Vaccine 33, 2710\u20132718 (2015).","journal-title":"Vaccine"},{"key":"26934_CR58","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/ni1449","volume":"8","author":"SA Khader","year":"2007","unstructured":"Khader, S. A. et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4\u2009+\u2009T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8, 369\u2013377 (2007).","journal-title":"Nat. Immunol."},{"key":"26934_CR59","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/mi.2012.135","volume":"6","author":"R Gopal","year":"2013","unstructured":"Gopal, R. et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol. 6, 972\u2013984 (2013).","journal-title":"Mucosal Immunol."},{"key":"26934_CR60","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1038\/mi.2014.136","volume":"8","author":"L Monin","year":"2015","unstructured":"Monin, L. et al. Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge. Mucosal Immunol. 8, 1099\u20131109 (2015).","journal-title":"Mucosal Immunol."},{"key":"26934_CR61","doi-asserted-by":"crossref","unstructured":"Shanmugasundaram, U., et al. Pulmonary Mycobacterium tuberculosis control associates with CXCR3- and CCR6-expressing antigen-specific Th1 and Th17 cell recruitment. JCI Insight 5, e137858 (2020).","DOI":"10.1172\/jci.insight.137858"},{"key":"26934_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00255-7","volume":"5","author":"C Counoupas","year":"2020","unstructured":"Counoupas, C. et al. Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis. NPJ Vaccines 5, 105 (2020).","journal-title":"NPJ Vaccines"},{"key":"26934_CR63","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1086\/590670","volume":"198","author":"J Hansen","year":"2008","unstructured":"Hansen, J. et al. Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J. Infect. Dis. 198, 758\u2013767 (2008).","journal-title":"J. Infect. Dis."},{"key":"26934_CR64","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26934-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26934-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T13:05:20Z","timestamp":1669986320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26934-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,18]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26934"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26934-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.18.435784","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,18]]},"assertion":[{"value":"29 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.M., C.A., and P.A. are co-inventors of a patent covering the use of H107 and derivatives. P.A. and I.R. are also co-inventors of patents covering the use of CAF\u00ae01 as an adjuvant. All rights have been assigned to Statens Serum Institut. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6658"}}